Li Man, Wei Na, Shi Han-Yu, Jing Xue-Jiao, Kan Xiao-Hong, Gao Hai-Qing, Xiao Yun-Ling
Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital of Shandong University, Jinan, Shandong, China.
J Geriatr Cardiol. 2023 Jul 28;20(7):495-508. doi: 10.26599/1671-5411.2023.07.002.
To investigate the prevalence of polypharmacy and potentially inappropriate medication (PIM) in elderly patients with heart failure (HF) and their impact on readmission and mortality.
We conducted a study of 274 participants aged 60 years or older with HF. The prevalence of polypharmacy (defined as the use of five or more medications) was calculated, and the 2019 American Geriatrics Society Beers criteria were applied to access PIMs. Medications and PIMs were characterized at admission and discharge, and changes in prescriptions during hospitalization were compared. The impact of polypharmacy and PIM on readmission and mortality were investigated.
The median age of this study population was 68 years old. The median number of prescribed drugs was 7 at admission and 10 at discharge. At discharge, 99.27% of all patients were taking five or more drugs. The incidence of composite endpoint and cardiovascular readmission increased with the number of polypharmacy within 6 months. The use of guideline-directed medical therapy reduced the incidence of composite endpoint events and cardiovascular readmission, while the use of non-cardiovascular medications increased the composite endpoint events. The frequency of PIMs was 93.79% at discharge. The incidence of composite endpoint events increased with the number of PIMs. "PIMs in older adults with caution" increased cardiovascular readmission and "PIMs based on kidney function" increased cardiovascular mortality. Several comorbidities were associated with cardiovascular mortality or non-cardiovascular readmission.
Polypharmacy and PIM were highly prevalent in elderly patients with HF, and their use was associated with an increased risk of composite endpoint events, readmission and mortality. Non-cardiovascular medications, "PIMs in older adults with caution", "PIMs based on kidney function" and several comorbidities were important factors associated with hospital readmission and mortality. Our findings highlight the importance of medication optimization in the management of HF in elderly patients.
调查老年心力衰竭(HF)患者多重用药及潜在不适当用药(PIM)的患病率及其对再入院和死亡率的影响。
我们对274名60岁及以上的HF患者进行了一项研究。计算多重用药(定义为使用五种或更多药物)的患病率,并应用2019年美国老年医学会Beers标准来评估PIM。在入院和出院时对药物和PIM进行特征分析,并比较住院期间处方的变化。研究多重用药和PIM对再入院和死亡率的影响。
该研究人群的中位年龄为68岁。入院时处方药物的中位数为7种,出院时为10种。出院时,所有患者中有99.27%服用五种或更多药物。6个月内,复合终点和心血管再入院的发生率随着多重用药数量的增加而增加。使用指南指导的药物治疗降低了复合终点事件和心血管再入院的发生率,而使用非心血管药物则增加了复合终点事件。出院时PIM的发生率为93.79%。复合终点事件的发生率随着PIM数量的增加而增加。“老年人慎用的PIM”增加了心血管再入院率,“基于肾功能的PIM”增加了心血管死亡率。几种合并症与心血管死亡率或非心血管再入院有关。
多重用药和PIM在老年HF患者中非常普遍,其使用与复合终点事件、再入院和死亡率风险增加有关。非心血管药物、“老年人慎用的PIM”、“基于肾功能的PIM”和几种合并症是与医院再入院和死亡率相关的重要因素。我们的研究结果强调了药物优化在老年HF患者管理中的重要性。